ANDATOPICALPASTE
Approved
Mar 1973
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
ORABASE HCA (hydrocortisone acetate) by Sandoz is clinical pharmacology cortifoam provides effective topical administration of an anti-inflammatory corticosteroid as adjunctive therapy of ulcerative proctitis. First approved in 1973.
Drug data last refreshed 1w ago
Mechanism of Action
CLINICAL PHARMACOLOGY Cortifoam provides effective topical administration of an anti-inflammatory corticosteroid as adjunctive therapy of ulcerative proctitis. Direct observations of methylene blue-containing foam have shown staining about 10 centimeters into the rectum.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Suppositories
Started Mar 2016
16 enrolled
Healthy
Company
Worked on ORABASE HCA at Sandoz? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.